Obesity Management: An ICER Policy Roundtable Discussion on the Assessment of Semaglutide and Tirzepatide

Author: Alyssa Guest

On November 13, 2025, Alyssa Guest, PharmD, Associate Director of Clinical Pharmacy at IPD Analytics, participated in the policy roundtable discussion at the Institute for Clinical and Economic Review (ICER)'s virtual Public Meeting, where industry experts and community members reviewed the clinical evidence and value of semaglutide (Wegovy®) and tirzepatide (Zepbound®) for obesity management. Her participation underscored IPD’s focus on supporting evidence-based discussions concerning high-impact therapies. ICER’s final evidence report is expected to be released in December 2025.